Publications by authors named "V Lucidi"
Cystic fibrosis is a life-shortening genetic disease caused by pathological variants of the cystic fibrosis transmembrane conductance regulator gene. The CFTR modulator therapy elexacaftor, tezacaftor and ivacaftor (ETI) rescues CFTR protein function and has made a significant impact on the lives of many people with CF. In Europe, ETI is currently available for people with CF who have at least one F508del mutation whilst the effect of ETI on rare CFTR variants remains unknown, albeit that many of such variants may be restored through ETI.
View Article and Find Full Text PDFBackground: Despite the increasing efficacy of chemotherapy, permanently unresectable colorectal liver metastases are associated with poor long-term survival. We aimed to assess whether liver transplantation plus chemotherapy could improve overall survival.
Methods: TransMet was a multicentre, open-label, prospective, randomised controlled trial done in 20 tertiary centres in Europe.
Background: Despite the increasing efficacy of chemotherapy (C), the 5-year survival rate for patients with unresectable colorectal liver metastases (CLM) remains around 10%. Liver transplantation (LT) might offer a curative approach for patients with liver-only disease, yet its superior efficacy compared to C alone remains to be demonstrated.
Methods: The TransMet randomised multicentre clinical trial (NCT02597348) compares the curative potential of C followed by LT versus C alone in patients with unresectable CLM despite stable or responding disease on C.
Article Synopsis
- The study aimed to compare the outcomes of laparoscopic and open major liver resection (hemihepatectomy) primarily for cancer patients, focusing on functional recovery time and other health-related factors.
- In a multicenter trial, 332 patients underwent surgery, with laparoscopic surgeries resulting in faster functional recovery (4 days vs. 5 days) and higher quality of life scores compared to open surgeries.
- The laparoscopic approach also led to a shorter time to start adjuvant systemic therapy for cancer patients, without negatively affecting resection margin status or overall cancer outcomes.